1.80
前日終値:
$1.80
開ける:
$1.79
24時間の取引高:
71,258
Relative Volume:
0.14
時価総額:
$208.17M
収益:
$232.79M
当期純損益:
$-88.69M
株価収益率:
-4.0733
EPS:
-0.4419
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.17%
1か月 パフォーマンス:
+9.09%
6か月 パフォーマンス:
-42.12%
1年 パフォーマンス:
+0.00%
Novabridge Biosciences Adr Stock (NBP) Company Profile
Compare NBP vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBP
Novabridge Biosciences Adr
|
1.80 | 220.89M | 232.79M | -88.69M | 0 | -0.4419 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novabridge Biosciences Adr Stock (NBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-06 | 再開されました | H.C. Wainwright | Buy |
| 2025-10-03 | 開始されました | Leerink Partners | Outperform |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2021-12-09 | 開始されました | Siebert Williams Shank | Buy |
| 2021-06-02 | 開始されました | Daiwa Securities | Buy |
| 2021-03-15 | 開始されました | Needham | Buy |
| 2021-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-25 | 開始されました | Piper Sandler | Overweight |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 開始されました | China Renaissance | Buy |
| 2020-02-11 | 開始されました | Jefferies | Buy |
すべてを表示
Novabridge Biosciences Adr (NBP) 最新ニュース
symbol__ Stock Quote Price and Forecast - CNN
Novabridge Biosciences ADR (NBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Cash Flow - TradingKey
Novabridge Biosciences ADR (NBP) Institutional Confidence - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.840|Chg%:+0.070 - TradingKey
Novabridge Biosciences ADR (NBP) Balance Sheet - TradingKey
TradingKey - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.790| - TradingKey
Novabridge Biosciences ADR (NBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Novabridge Biosciences ADR (NBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Novabridge Biosciences ADR (NBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NBP|Novabridge Biosciences ADR|Price:1.770| - TradingKey
Novabridge Biosciences ADR (NBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026 - GlobeNewswire Inc.
NovaBridge Biosciences SVP sells $3,991 in ordinary shares - Investing.com
Empowering Investor Success - Morningstar
NBPNovaBridge Biosciences ADR Latest SEC Filings - Finviz
NovaBridge appoints Srishti Gupta as new CEO effective July 1 - Investing.com
NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP) - TradingView
Novabridge Biosciences ADR (NBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Novabridge Biosciences ADR - TradingKey
NovaBridge Biosciences (NBP) corrects major holder stakes in 20-F/A filing - Stock Titan
NovaBridge Biosciences stock surges on FDA Fast Track nod By Investing.com - Investing.com South Africa
NovaBridge Biosciences stock surges on FDA Fast Track nod - Investing.com
Number of shareholders of NovaBridge Biosciences Sponsored ADR – GETTEX:0VY - TradingView
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares By Investing.com - Investing.com India
NovaBridge Biosciences SVP Claire Xu sells $13,766 in shares - Investing.com
Sean Cao, NovaBridge Biosciences chief BD officer, sells $42,584 in shares - Investing.com
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
NovaBridge Biosciences president buys $577,300 in company shares By Investing.com - Investing.com India
NovaBridge Biosciences president buys $577,300 in company shares - Investing.com
NovaBridge appoints Mark Hagler as president, chief commercial officer - Investing.com
NovaBridge Biosciences (NASDAQ: NBP) posts 2025 loss, extends cash runway to 2028 - Stock Titan
H.C. Wainwright reiterates NovaBridge stock rating on FDA feedback - Investing.com India
NovaBridge gets FDA nod for accelerated approval path for givastomig - Investing.com
NovaBridge reports positive Phase 2a data for eye disease drug - Investing.com
NovaBridge enrolls first patient in phase 2 gastric cancer study - Investing.com
NovaBridge Biosciences stock price target raised to $9 by H.C. Wainwright - investing.com
NBP Stock Price and Chart — NASDAQ:NBP - TradingView
NovaBridge chairman to purchase up to $5 million in company shares - Investing.com
NovaBridge stock soars after positive gastric cancer drug results - Investing.com
BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
What is the current Price Target and Forecast for NovaBridge Biosciences (NBP) - Zacks Investment Research
NovaBridge Biosciences Share Price ADS SPON - Hargreaves Lansdown
NovaBridge Biosciences (0VY.F) stock price, news, quote and history - Yahoo Finance Singapore
What date does NovaBridge Biosciences's (NBP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
NBP Stock Price | Analyst Target 9.00 & Consensus - eToro
IMAB Stock Price, Quote & Chart | I-MAB-SPONSORED ADR (NASDAQ:IMAB) - ChartMill
I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift - Investing.com
NBP: Transforming into a global biotech, rebranding, and pursuing dual NASDAQ/HKEX listing - TradingView
Novabridge Biosciences Adr (NBP) 財務データ
収益
当期純利益
現金流量
EPS
Novabridge Biosciences Adr (NBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Xu Cong Claire | SVP, Clinical Development |
Jul 06 '26 |
Sale |
0.89 |
4,485 |
3,992 |
298,101 |
| Dennis Phillip Andrew | Chief Medical Officer |
Jun 18 '26 |
Sale |
0.66 |
8,494 |
5,606 |
157,941 |
| Xu Cong Claire | SVP, Clinical Development |
Jun 01 '26 |
Sale |
3.94 |
3,494 |
13,766 |
290,154 |
| Cao Sean Wuxiong | See Remarks |
May 14 '26 |
Sale |
1.99 |
21,399 |
42,584 |
35,073 |
大文字化:
|
ボリューム (24 時間):